[Fragment-based screening: a promising avenue for drug design].
Fragment-based screening is now recognised as a powerful method for the design of novel potent molecules against therapeutic protein targets including challenging targets. Here, the main concepts used in the fragment-based drug design approach are reviewed, together with the reasons for its success. Methods and strategies used to identify, validate and select fragments are discussed. Future challenges and developments that are expected for the next decade are presented.
Institut des sciences analytiques, UMR CNRS 5280, 5, rue de La Doua, 69100 Villeurbanne, France.
Isabelle
I
Krimm
D000818:Animals; D001665:Binding Sites; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D005544:Forecasting; D006801:Humans; D008024:Ligands; D015394:Molecular Structure; D058990:Molecular Targeted Therapy; D008970:Molecular Weight; D019906:Nuclear Magnetic Resonance, Biomolecular / Q000379:methods; D011485:Protein Binding; D013329:Structure-Activity Relationship
D008024:Ligands